|Title:||Update: Arkansas Medicaid Drug Review Committee - May 13, 2020|
UPDATE: Due to the changes being made because of COVID-19, the next
DRC Board meeting will be held in a virtual format. Arkansas Medicaid Drug Review Committee will be conducting a ZOOM webinar to facilitate our upcoming meeting. Below you will find a link to register for the webinar. Each person attending the meeting must register at the link below.
This is a public meeting, and invitations to the public have been sent using our current list of interested parties. This list includes industry representatives and members of the media. All public attendees will be muted and will be unable to make comments. Only Committee members, DHS staff and pre-determined speakers will be allowed to make
INVITATION FOR ATTENDEES TO REGISTER:
You are invited to a Magellan
When: May 13, 2020 09:00 AM
Topic: AR P&T Committee
Please register for the date and
The Arkansas Medicaid DRC agenda for the May 13, 2020 meeting is attached below and is available on the AR Medicaid website. As of this moment, I have not received a request to speak for any medication listed on the attached agenda.
For those drug companies that have a drug listed on the agenda and wish to submit a request to make public comments on your drug, the deadline to submit the request with the required data is April 29, 2020 by close of business. The documentation provided will be forwarded to our Committee members prior to the meeting.
Per the current DRC bylaws:
6.02 Outside Speakers —Outside speakers with clinical or scientific credentials or patient experience pertinent to a product or topic that is posted on the upcoming DRC meeting agenda may request to speak on that product or topic. Requests to speak at the DRC meeting must be made in writing to the Chairperson at least two (2) weeks before the DRC meeting date, and must specify:
(1) The speaker’s name, title, and organization;
(2) Contact information for the speaker including address, telephone number, and email;
(3) The agenda item(s) which the speaker intends to address;
(4) Prepared comments not to include any manufacturer’s package insert; and
(5) An electronic copy of any presentation materials the speaker intends to use, if any.
This information shall be included in information sent to Committee members two (2) weeks prior to the Committee meeting. Presentations or public comments given at the DRC meeting are limited to a total of two (2) minutes per drug, which may be shared by multiple speakers. This time limit does not include responses to any questions raised by DRC members during the course of the meeting.
Interested parties for products or topics listed on the quarterly meeting agenda may reach out to the Arkansas Medicaid Pharmacy Program after the agenda is posted to request a meeting with staff prior to the DUR Board meeting. These meetings may be held in-person or by conference all up to three (3) weeks prior to the DUR meeting and shall be no
NOTE: Speakers may no longer sign up at the meeting. Only those speakers whom have submitted their public comments will be allowed to address the Committee.
At this time, a decision to make this meeting virtual has not been made. Once a decision is made, you will be notified.
Please stay safe!
Cindi Pearson, Pharm. D.
DMS/Arkansas Medicaid Pharmacy Program